Day 2 at analytica Lab India 2026
The second day of the technical conference held in Hall 5’s first-floor conference halls at analytica Lab India 2026 — the three-day event running alongside the trade floor at HITEX Exhibition Centre, Hyderabad — turned from analytical method development to laboratory digitalization. Conducted in collaboration with the Indian Pharmaceutical Alliance (IPA), Day 2 addressed the shift from reactive quality-control culture to algorithmic quality architectures, and the structural economics of laboratory automation.
Quality Culture & Proactive Compliance
Pravin Kulkarni of Light Pharma opened the day’s proceedings with a presentation on quality culture sustainability, arguing that despite decades of compliance training, pharmaceutical quality control laboratories often fall into a recurring trap: treating quality compliance as a retrospective documentation exercise rather than a predictive science. He demonstrated that true operational sustainability occurs only when laboratory personnel are equipped with computerized systems that automatically flag deviations, remove the fear of reporting anomalies, and eliminate the manual data-entry burdens that invite human error — reframing the traditional reactive model (run the assay, wait for an out-of-specification or out-of-trend breach, conduct a retrospective root-cause analysis, then retrain staff) around predictive, multi-source monitoring instead.
The IPA Panel: “The AI Quality Investigator”
The centerpiece of Day 2 was an extended panel discussion convened by the IPA and moderated by its Senior Technical Advisor, Dr. Rajiv Desai, titled “The AI Quality Investigator: Can AI Transform Pharmaceutical Investigations from ‘Finding the Cause’ to ‘Finding the Pattern’?” The panel divided roughly along two lines: predictive pattern identification, represented by Dr. BM Rao of Qdot Associates and Dr. Damodharan Muniyandi of Sai Life Sciences, and regulatory integrity and GxP explainability, represented by Dr. Girish Kapur of USP India and M. Gopi Reddy of QBC Consulting, formerly Vice President of Global Quality and Compliance at Sun Pharma.
Dr. Desai opened by noting that for decades, pharmaceutical laboratories have relied on retrospective frameworks — Ishikawa fishbone diagrams and 5-Why root-cause methodologies — that frequently conclude with vague findings of “analyst error,” followed by routine retraining. Dr. BM Rao argued that human analysts reviewing isolated chromatographic traces routinely miss the multivariate patterns that precede an analytical failure, and that machine learning models applied across historical chromatography data systems, laboratory information management systems, and building management systems can detect subtle interactions — such as a 1.5°C shift in ambient column temperature interacting with a specific mobile-phase batch — that inevitably cause an assay to fail. Dr. Damodharan Muniyandi offered evidence from active contract research settings, describing predictive algorithms monitoring HPLC pump telemetry that identified subtle variations in piston stroke pressure signaling seal degradation hours before baseline drift occurred, allowing maintenance before commercial batch testing was compromised.
The panel’s regulatory specialists pushed back with caution. M. Gopi Reddy emphasized that global health authorities operating under US FDA 21 CFR Part 11 and EU GMP Annex 11 require complete, deterministic, and explainable audit trails: if an AI model flags an anomaly or invalidates a run, its decision pathway must be transparent and auditable, and complex deep-learning networks that function as “black boxes” cannot be validated for automated GxP investigations without documentation explaining how the pattern was identified. Dr. Girish Kapur reinforced that while pharmacopeias and regulators encourage digital innovation, final accountability for releasing a batch of medicine to patients remains with human quality heads.
Keynote and CXO Panel: The Lab 5.0 Opportunity
During the afternoon session, Knowledge Partner Coherent Market Insights presented its market analysis. Mohit Shrivastava, AVP of Research and Consulting at CMI, delivered a keynote titled “Lab 5.0 in India: Laboratory Automation, Informatics and AI Market Opportunity, 2026–2033,” built around a five-stage laboratory maturity framework: a Digitized Laboratory (standalone LIMS, elimination of paper records, manual instrument parameter input); an Automated Laboratory (robotic liquid handling, auto-samplers, discrete CDS/LIMS integration for single workflows); a Connected Laboratory (bidirectional integration across LIMS, ELN, ERP, and MES with centralized automated audit trails); a Predictive Laboratory (machine learning engines analyzing pooled CDS/LIMS data to forecast instrument drift and method failure); and, at the top of the spectrum, an Autonomous Lab 5.0 (closed-loop robotics, self-calibrating and self-healing fluidics, automated validation, and dynamic real-time release).
Shrivastava noted that adoption across India remains divided: Tier-1 generic formulation plants have established connected laboratories and are piloting predictive environments to manage export testing volumes, while many domestic academic and secondary research institutions remain at the digitized stage. Driven by export compliance pressure, biosimilar manufacturing, and federal biomanufacturing incentives, CMI projects the Indian laboratory automation, informatics, and AI market will grow at a compound annual rate exceeding 12.8% through 2033.
The CXO panel that followed, moderated by Shrivastava, featured Appasaheb Kandagal of Smilax Laboratories, Dr. Jugnu Jain of Sapien Biosciences, Dr. Ramesh Jagadeesan of Aragen Life Sciences, and Venkat Kamalakar Bundla of Garphi Biosciences. The executives agreed that the primary barrier to achieving a Lab 5.0 architecture is data fragmentation: legacy laboratory hardware from different manufacturers frequently uses proprietary, closed data formats, creating operational silos. Dr. Jugnu Jain pointed out that in translational biobanking and personalized medicine specifically, integrating high-dimensional phenotypic patient data with molecular sequencing is impossible without vendor-agnostic, open-source data standards.
